No abstract

No abstract

An algae-based biorefinery relies on the efficient use of algae biomass through its fractionation of several valuable/bioactive compounds that can be used in industry. If this biorefinery includes green platforms as downstream processing technologies able to fulfill the requirements of green chemistry, it will end-up with sustainable processes. In the present study, a downstream processing platform has been developed to extract bioactive compounds from the microalga Isochrysis galbana using various pressurized green solvents. Extractions were performed in four sequential steps using (1) supercritical CO2 (ScCO2), (2) ScCO2/ethanol (Gas Expanded Liquid, GXL), (3) pure ethanol, and (4) pure water as solvents, respectively. The residue of the extraction step was used as the raw material for the next extraction. Optimization of the ScCO2 extraction was performed by factorial design in order to maximize carotenoid extraction. During the second step, different percentages of ethanol were evaluated (15%, 45% and 75%) in order to maximize the extraction yield of fucoxanthin, the main carotenoid present in this alga; the extraction of polar lipids was also an aim. The third and fourth steps were performed with the objective of recovering fractions with high antioxidant activity, eventually rich in carbohydrates and proteins. The green downstream platform developed in this study produced different extracts with potential for application in the food, pharmaceutical and cosmetic industries. Therefore, a good approach for complete revalorization of the microalgae biomass is proposed, by using processes complying with the green chemistry principlesThe authors acknowledge funding from the EU MIRACLES project (7th Framework Program - Grant Agreement No. 613588). B.G.L. thanks MINECO (Ministerio de Economía y Competitividad) for her Juan de la Cierva postdoctoral research contract. M.H. thanks MINECO for his Ramón y Cajal postdoctoral research contract

No abstract

No abstract

Milk and dairy products containing milk fat are major food sources of saturated fatty acids, which have been linked to increased risk of cardiovascularrelated clinical outcomes such as cardiovascular disease (CVD), coronary heart disease (CHD), and stroke. Therefore, current recommendations by health authorities advise consumption of low-fat or fat-free milk. Today, these recommendations are seriously questioned by meta-analyses of both prospective cohort studies and randomized controlled trials (RCTs) reporting inconsistent results. The present study includes an overview of systematic reviews and meta-analyses of follow-up studies, an overview of meta-analyses involving RCTs, and an update on meta-analyses of RCTs (2013-2018) aiming to synthesize the evidence regarding the influence of dairy product consumption on the risk of major cardiovascular-related outcomes and how various doses of different dairy products affect the responses, as well as on selected biomarkers of cardiovascular disease risk, i.e., blood pressure and blood lipids. The search strategies for both designs were conducted in the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science databases from their inception to April 2018. From the 31 full-text articles retrieved for cohort studies, 17 met the eligibility criteria. The pooled risk ratio estimated for the association between the consumption of different dairy products at different dose-responses and cardiovascular outcomes (CVD, CHD, and stroke) showed a statistically significant negative association with RR values <1, or did not find evidence of significant association. The overview of 12 meta-analyses involving RCTs as well as the updated meta-analyses of RCTs did not result in significant changes on risk biomarkers such as systolic and diastolic blood pressure and total cholesterol and LDL cholesterol. Therefore, the present study states that the consumption of total dairy products, with either regular or low fat content, does not adversely affect the risk of CVD.

No abstract

No abstract